GSDMD and neoplasm: The VNP-GD/EI-NP@Gel treatment showed a better tumor inhibition than the VNP-GD@Gel treatment group indicating a stronger systemic immune activation induced by the pyroptosis-mediated tumor antigen release that resulted from the combination of GSDMD-induced and ESCRT III inhibition-boosted tumor cell pyroptosis.